Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xenija Kaiser

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|August 18, 2025
Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancerSylwia A Stefańczyk, Xenija Kaiser, Ilona Hagelstein, et al.
Immunotargets and Therapy|February 19, 2026
Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3)Sylwia A Stefańczyk, Xenija Kaiser, Ilona Hagelstein, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|August 18, 2025
Fc-optimized CD276 antibody enhances NK cell activation against non-small cell lung cancerSylwia A Stefańczyk, Xenija Kaiser, Ilona Hagelstein, et al.
Immunotargets and Therapy|February 19, 2026
Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3)Sylwia A Stefańczyk, Xenija Kaiser, Ilona Hagelstein, et al.
Pageof 1